

# HALOBETASOL PROPIONATE + TAZAROTENE TOPICAL LOTION SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established  
by Alberta government sponsored drug programs.

PATIENT INFORMATION				COVERAGE TYPE	
LAST NAME	FIRST NAME	INITIAL	<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other _____		
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER				
ADDRESS	CITY	PROV	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER	

PRESCRIBER INFORMATION					
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION		
ADDRESS			<input type="checkbox"/> CPSA	<input type="checkbox"/> ACO	REGISTRATION NUMBER
			<input type="checkbox"/> CARNA	<input type="checkbox"/> ADA+C	
CITY, PROVINCE			PHONE	FAX	
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED		

**Criteria for coverage**

"Special authorization coverage may be provided for improving the signs and symptoms of moderate to severe plaque psoriasis in adult patients (18 years of age and older) who meet ALL of the following criteria:

- Patients must have a clinical diagnosis of plaque psoriasis with all of the following characteristics:
  - an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4 (severe), and
  - an area of plaque psoriasis appropriate for topical treatment covering a body surface area (BSA) of 3% to 12%, and
- Patients must have not adequately responded to a topical high-potency corticosteroid and for whom the addition of a second topical medication would be appropriate.

Initial coverage may be approved for 12 weeks.

For continued coverage beyond 12 weeks, the patient must meet the following criteria:

- The patient must be assessed by the prescriber after the initial 8 to 12 weeks of therapy to determine response.
- The prescriber must confirm, in writing, that the patient is a 'responder' with an IGA score of 'clear' or 'almost clear' (0 or 1).

Continued coverage may be granted for 12 months."

The product is eligible for auto-renewal after continued coverage criteria have been met.

**Please provide the following information for ALL requests**

**Diagnosis**

Moderate to severe plaque psoriasis       Other (please specify) \_\_\_\_\_

**Please provide the following information for all INITIAL requests for treatment-naive and treatment-experienced patients**

1) The patient has an area of plaque psoriasis appropriate for topical treatment covering a body surface area (BSA) of 3% to 12%	<input type="checkbox"/> Yes	<input type="checkbox"/> No
2) The patient has not adequately responded to a topical high-potency corticosteroid and the addition of a second topical medication is appropriate	<input type="checkbox"/> Yes	<input type="checkbox"/> No

3) **Pre-treatment** Investigator's Global Assessment (IGA) score \_\_\_\_\_ and Date \_\_\_\_\_

**Please provide the following information for RENEWAL requests and for INITIAL requests for treatment-experienced patients**

4) **Current** Investigator's Global Assessment (IGA) score \_\_\_\_\_ and Date \_\_\_\_\_

**Additional information relating to request**

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to <b>Alberta Blue Cross, Clinical Drug Services</b> <b>10009 108 Street NW, Edmonton, Alberta T5J 3C5</b> <b>FAX 780-498-8384</b> in Edmonton • <b>1-877-828-4106</b> toll free all other areas
------------------------	-------------------	---

**ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.**